Suppr超能文献

术前uPAR-PET/CT在口腔和口咽鳞状细胞癌区域淋巴结分期中的诊断价值:一项前瞻性II期试验

Diagnostic Value of Preoperative uPAR-PET/CT in Regional Lymph Node Staging of Oral and Oropharyngeal Squamous Cell Carcinoma: A Prospective Phase II Trial.

作者信息

Lawaetz Mads, Christensen Anders, Juhl Karina, Lelkaitis Giedrius, Karnov Kirstine, Carlsen Esben Andreas, Charabi Birgitte W, Loft Annika, Czyzewska Dorota, Buchwald Christian von, Kjaer Andreas

机构信息

Department of Otolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.

Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Copenhagen University Hospital-Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark.

出版信息

Diagnostics (Basel). 2023 Oct 25;13(21):3303. doi: 10.3390/diagnostics13213303.

Abstract

The detection of lymph node metastases is a major challenge in oral and oropharyngeal squamous cell carcinoma (OSCC and OPSCC). Ga-NOTA-AE105 is a novel positron emission tomography (PET) radioligand with high affinity to urokinase-type plasminogen activator receptor (uPAR), a receptor expressed on the surfaces of tumor cells. The aim of this study was to investigate the diagnostic value of uPAR-PET/CT (computerized tomography) in detecting regional metastatic disease in patients with OSCC and OPSCC compared to the current imaging work-up. In this phase II trial, patients with OSCC and OPSCC referred for surgical treatment were prospectively enrolled. Before surgery, Ga-NOTA-AE105 uPAR-PET/CT was conducted, and SUVmax values were obtained from the primary tumor and the suspected lymph nodes. Histology results from lymph nodes were used as the standard of truth of metastatic disease. The diagnostic values of Ga-uPAR-PET/CT were compared to conventional routine preoperative imaging results (CT and/or MRI). The uPAR expression in resected primary tumors and metastases was determined by immunohistochemistry and quantified digitally (H-score). A total of 61 patients underwent uPAR-PET/CT. Of the 25 patients with histologically verified lymph node metastases, uPAR-PET/CT correctly identified regional metastatic disease in 14 patients, with a median lymph node metastasis size of 14 mm (range 3-27 mm). A significant correlation was found between SUVmax and the product of the H-score and tumor depth (r = 0.67; = 0.003). The sensitivity and specificity of uPAR-PET/CT in detecting regional metastatic disease were 56% and 100%, respectively. When added to CT/MRI, uPAR-PET was able to upstage 2/11 (18%) of patients with occult metastases and increase the sensitivity to 64%. The sensitivity and specificity of Ga-NOTA-AE105 uPAR-PET/CT were equivalent to those of CT/MRI. The significant correlation between SUVmax and uPAR expression verified the target specificity of Ga-NOTA-AE105. Despite the target specificity, the sensitivity of imaging is too low for nodal staging and it cannot replace neck dissection.

摘要

淋巴结转移的检测是口腔和口咽鳞状细胞癌(OSCC和OPSCC)中的一项重大挑战。Ga-NOTA-AE105是一种新型正电子发射断层扫描(PET)放射性配体,对尿激酶型纤溶酶原激活物受体(uPAR)具有高亲和力,uPAR是一种在肿瘤细胞表面表达的受体。本研究的目的是调查与当前影像学检查相比,uPAR-PET/CT(计算机断层扫描)在检测OSCC和OPSCC患者区域转移性疾病中的诊断价值。在这项II期试验中,前瞻性纳入了因手术治疗而转诊的OSCC和OPSCC患者。手术前,进行了Ga-NOTA-AE105 uPAR-PET/CT检查,并从原发性肿瘤和可疑淋巴结中获取SUVmax值。淋巴结的组织学结果用作转移性疾病的金标准。将Ga-uPAR-PET/CT的诊断价值与传统的术前常规影像学检查结果(CT和/或MRI)进行比较。通过免疫组织化学确定切除的原发性肿瘤和转移灶中的uPAR表达,并进行数字量化(H评分)。共有61例患者接受了uPAR-PET/CT检查。在25例经组织学证实有淋巴结转移的患者中,uPAR-PET/CT正确识别出14例区域转移性疾病,淋巴结转移的中位大小为14mm(范围3-27mm)。发现SUVmax与H评分和肿瘤深度的乘积之间存在显著相关性(r = 0.67;P = 0.003)。uPAR-PET/CT检测区域转移性疾病的敏感性和特异性分别为56%和100%。当与CT/MRI联合使用时,uPAR-PET能够使2/11(18%)隐匿性转移患者的分期上调,并将敏感性提高到64%。Ga-NOTA-AE105 uPAR-PET/CT的敏感性和特异性与CT/MRI相当。SUVmax与uPAR表达之间的显著相关性证实了Ga-NOTA-AE105的靶向特异性。尽管具有靶向特异性,但成像的敏感性对于淋巴结分期来说过低,并且不能替代颈部清扫术。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3b1/10649042/4a5749fe8ea3/diagnostics-13-03303-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验